A randomized, crossover pilot study comparing
glycemic control and satisfaction with an indwelling
catheter (I-PORT Advance) for insulin administration in
children and adolescents with type 1 diabetes on
basal-bolus treatment

Maltoni G, Martini AL, Perri AM, Rollo A, Balsamo C, Zucchini S.
S.Orsola Malpighi Hospital - University of Bologna, Pediatric Clinic - Endocrine Unit, Bologna, Italy

Background

It is known that an intensive insulin treatment allows to achieve a good metabolic control and prevent the long term microvascular complications. Basal-bolus regimen is considered as the best treatment for type 1 diabetes (T1D) in the pediatric age. However, to be adherent to the basal-bolus schedule, in everyday life children with T1D and their families have to inject insulin several times for meals, snacks and corrections for hyperglycaemic peaks. The needle-fear and discomfort felt by the child and parents/caregivers in insulin administration is one of the main obstacle to a good therapeutic compliance.

Objective

To compare glycaemic control and satisfaction with a new injection port (I-PORT Advance), through which insulin can be injected subcutaneously from a syringe/pen without repeated needle punctures of the skin, to multiple daily insulin administration (MDI).

Population and Study design

Twenty subjects (5 M, mean age 9.5±2.6years, mean T1D-duration 3.1±2.3yrs) were enrolled. They were randomly assigned to group A (starting using I-PORT) and B (on traditional MDI). Participants were trained to change the device every 3 days and to inject both basal and bolus insulins through it. Subjects were invited to move to a strict basal-bolus regimen (requiring more insulin injections for meals, snacks and hyperglycaemic peaks). After 8 weeks the 2 groups switched to the other arm. HbA1c was detected at baseline, before the cross-over and at the end of the study (16 weeks). A questionnaire was provided to collect satisfaction about the new device.

Results

Two participants dropped out and were excluded from the analysis. Mean baseline HbA1c was 8.02±1% (64±11 mmol/mol), mean HbA1c after I-PORT period 7.53±0.7% (58±8mmol/mol) whereas mean HbA1c on traditional MDI 7.92±0.9% (63±9.3mmol/mol) (p=0.06). No dka or severe hypoglycaemic episodes occurred. At the end of the study 15/20 (75%) of participants appreciated I-PORT and decided to maintain it.

Conclusions

In this pilot study I-PORT has proven to be safe and seems to improve metabolic control in children during real-life setting and, attenuating the discomfort of multiple injections through the device, allowed to follow more strictly basal-bolus regimen. Children and adolescents seem to tolerate and appreciate this new device.